tiprankstipranks
Wuxi Biologics (Cayman) Inc. (MX:2269N)
:2269N
Mexico Market
2269N
Wuxi Biologics (Cayman)
RESEARCH TOOLSreports

Wuxi Biologics (Cayman) (2269N) Income Statement

0 Followers

Wuxi Biologics (Cayman) Income Statement

Last quarter (Q2 2026), Wuxi Biologics (Cayman)'s total revenue was ¥11.79B, an increase of 37.47% from the same quarter last year. In Q2, Wuxi Biologics (Cayman)'s net income was ¥2.44B. See Wuxi Biologics (Cayman)’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
¥ 21.79B¥ 18.68B¥ 17.03B¥ 15.27B¥ 10.29B
Gross Profit
¥ 10.02B¥ 7.65B¥ 6.83B¥ 6.72B¥ 4.83B
Operating Expenses
¥ 3.38B¥ 2.68B¥ 2.38B¥ 2.38B¥ 1.64B
Depreciation and Amortization
¥ 1.28B¥ 1.44B¥ 1.17B¥ 800.67M¥ 481.78M
EBITDA
¥ 7.92B¥ 6.43B¥ 5.50B¥ 6.22B¥ 4.51B
Operating Income
¥ 6.64B¥ 4.97B¥ 4.45B¥ 4.34B¥ 3.19B
Other Income/Expenses
¥ 617.16M¥ -139.41M¥ -276.39M¥ 1.02B¥ 805.01M
Pretax Income
¥ 7.26B¥ 4.83B¥ 4.17B¥ 5.36B¥ 3.99B
Net Income
¥ 4.91B¥ 3.36B¥ 3.40B¥ 4.42B¥ 3.39B
Per Share Metrics
Basic EPS
¥ 1.16¥ 0.82¥ 0.82¥ 1.06¥ 0.81
Diluted EPS
¥ 1.16¥ 0.78¥ 0.77¥ 1.01¥ 0.77
Weighted Average Shares Outstanding
 4.18B 4.08B 4.16B 4.17B 4.40B
Weighted Average Shares Outstanding (Diluted)
 4.18B 4.23B 4.35B 4.38B 4.42B
Currency in CNY

Wuxi Biologics (Cayman) Earnings and Revenue History